Business
OraSure Technologies Appoints Lisa Nibauer as Infectious Disease Business Unit Lead
Board Change Also Announced BETHLEHEM, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic
About this update from Orasure Technologies, Inc.
[{"type":"text","content":"Board Change Also Announced\nBETHLEHEM, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Lisa Nibauer has been appointed Executive Vice President, Business Unit Leader, Infectious Disease. She will replace Tony Zezzo, who has announced that he will retire from the Company. Mr. Zezzo has agreed to work with Ms. Nibauer to ensure smooth and successful transition of duties, while maintaining his current pivotal role in OraSure’s COVID-19 activities. His official retirement date will be mutually determined. Ms. Nibauer will join the Company on May 11, 2020.\n Ms. Nibauer joins OraSure from BD Becton Dickinson, Inc. (“BD”), where she spent eight years, most recently as VP/GM, Global Medication Delivery Solutions. In that role, she had general management responsibility for $1.6 billion in annual revenue and a team of over 300 people globally and was also accountable for the Global Marketing function for the largest business unit in BD. Prior to that, also at BD, Ms. Nibauer held the positions of VP/GM, Global PreAnalytical Systems Business & Global Marketing and Senior Director, Global Blood Collection Acquisition Platform. Prior to joining BD, she held general management, sales and marketing positions with increasing responsibilities at Adlens Beacon Inc., Schering-Plough Consumer Healthcare (Bayer), General Mills, Elf Atochem, and ICI (now part of AstraZeneca, Henkel and AkzoNobel). Ms. Nibauer earned an M.B.A. from UCLA Anderson School of Management and a B.S. in Chemical Engineering from Lehigh University. Mr. Zezzo has served as OraSure’s Executive Vice President, Business Unit Leader, Infectious Disease since 2017, and prior to that served as Executive Vice President, Marketing and Sales. Mr. Zezzo’s contributions to the company include the commercialization of the OraQuick® HCV Rapid Antibody test, the first FDA-approved, CLIA-waived rapid test for Hepatitis C; and the growth of its HIV business to $43,000,000 in 2019. Prior to joining OraSure in 2011, Mr. Zezzo was Vice President, North America Sales and Marketing at the Ortho-Clinical Diagnostics division of Johnson & Johnson. He also held a series of sales and marketing positions at Johnson & Johnson....